Hi Everyone - partly inspired by attending the recent EA Global London conference a couple of weeks ago, I've written a CGD Blog with some thoughts on EA's approach to prioritisation and methods in health economics (specifically Health Technology Assessment). This is a link post and as CGD staff I have to post on our platform, but since the key target audience is EAs, I'd be delighted to hear thoughts from this community. I'll be sure to monitor the comments section and perhaps the discussion will feed into future work.
The differences between EA and health econ I highlight include:
1. Approaches to generalising cost-effectiveness evidence
2. Going beyond cost-effectiveness in determining value
3. Deliberative appraisal
4. Institutionalisation of a participatory process
Please click through for the full blog.
Thanks! To clarify about moral uncertainty/pluralism - a caricatured EA approach might use CEA to evaluate how well different interventions maximise units of a particular benefit (e.g. DALYs, lives saved, ROI), and then follow those results to fulfil a consequentialist ethic. HTA seems like a method that could additionally weight equity, fairness, or benefit to the worst off, such that it would be more inclusive of prioritarian or justice-based views. HTA's greater emphasis on participation by different stakeholders also seems more amenable to considering a plurality of worldviews, rather than reliance on those of a small set of donors and analysts.
So all that sounds quite good to me, but I'm aware that there may be a trade-off where EA loses some its weirdness, such that high-impact but niche interventions and cause areas would be neglected if EA became more like the rest of the aid landscape. I'm not sure what to think here.